The role of hormone replacement therapy and the risk of development of ovarian cancer
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 1
Abstract
Hormone replacement therapy (HRT), which is mainly used to relieve climacteric symptoms, increases a woman’s risk for breast cancer, uterine endometrial cancer, but the association with ovarian cancer is less clear. Based upon epidemiological research there is evidence that steroids hormones, primarily estrogens and progesterone have an impact on ovarian carcinogenesis. The latest data have indicated that estrogens favour neoplastic transformation within the ovarian surface epithelium. There has been demonstrated a differential expression of ER alpha or beta during ovarian carcinogenesis, with an overexpression of ER alpha as compared with ER beta in cancer. The loss of ER-beta expression may be an important event leading to the development of ovarian cancer. ER- beta is a regulator of proliferation and motility of ovarian cancer cells. On the other hand, high progesterone levels offer a protection against development of ovarian carcinoma and overexpression progesterone receptors, which in turn, is associated with favourable prognosis in patients with ovarian cancer. Recent prospective epidemiological studies have indicated that hormone replacement therapy in post menopausal women may increase ovarian cancer incidence and mortality, especially in the group of women who have undergone HRT for more than 10 years. Physicians counselling women about HRT must consider the unique needs of each patient, and attempt to weigh the benefits and risks on an individual basis.
Authors and Affiliations
Lubomir Bodnar, Gabriel Wcisło, Agnieszka Gąsowska-Bodnar, Cezary Szczylik
Keywords
Related Articles
- EP ID EP123523
- DOI -
- Views 54
- Downloads 0
Rak jelita grubego w świetle współczesnych badań molekularnych
Populacja ludzi dotknięta rakiem jelita grubego to mieszkańcy państw wysoko uprzemysłowionych. Rocznie stwierdza się 875 tys. nowych przypadków tej choroby, a umiera 570 tys. osób. Ogromna większość chorych to przypadki...
The role of allogeneic hematopoietic stem transplantation in the treatment of solid tumors
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become an established therapeutic approach for many hematological malignancies. Early attempts in transplantation usually used the myeloablative methodol...
Psychological aspects of press reports vs. actual possibilities of genetic testing in oncology
Breast cancer is the most common cancer in women in Poland. Although the incidence rate is constantly increasing, breast cancer mortality has recently been stable. This phenomenon may be explained by combined benefits...
Jak działa 5-fluorouracyl
5-fluorouracyl (5-FU) jest jednym z najskuteczniejszych chemioterapeutyków, używanych w leczeniu raka jelita grubego. Jest on również stosowany u chorych na raka piersi, głowy i szyi, przełyku, żołądka oraz w przypadku k...
Leczenie celowane chorych na raka jelita grubego – aktualny stan wiedzy
Ostatnie osiągnięcia w dziedzinie terapii celowanej przyniosły chorym na raka jelita grubego dalszą poprawę przeżycia. Szczególne znaczenie kliniczne uzyskały 2 przeciwciała monoklonalne skierowane przeciw naczyniowemu...